Ipamorelin vs Sermorelin

Ipamorelin vs Sermorelin research guide comparing peptide structure

Research guide

Ipamorelin vs Sermorelin

Two growth hormone secretagogues, two different receptors. How they compare for laboratory research.

Ipamorelin and Sermorelin are two of the most widely studied peptides in growth hormone (GH) research. Both stimulate GH release from the pituitary, which is why they’re often grouped together. But they work through completely different receptors, differ greatly in size, and behave differently in study models.

This guide compares their structure, mechanism and selectivity, explains why researchers sometimes study them side by side, and covers correct laboratory handling for both.

Ipamorelin vs Sermorelin At a glance

SermorelinIpamorelin
ClassGHRH analogueGrowth hormone secretagogue (ghrelin mimetic)
Length29 amino acids5 amino acids
Molecular weight≈ 3,357.9 g/mol≈ 711.9 g/mol
Molecular formulaC149H246N44O42SC38H49N9O5
Receptor targetGHRH receptor (GHRH-R)Ghrelin receptor (GHS-R1a)
Notable research featureMirrors the body’s own GH-releasing signalHighly selective for GH release in animal studies
Form suppliedLyophilised powderLyophilised powder

What is Sermorelin?

Sermorelin is a synthetic peptide made up of the first 29 amino acids of human growth hormone-releasing hormone (GHRH), sometimes written as GRF(1-29). Research established that this short fragment keeps the full biological activity of the 44-amino-acid natural hormone, which made it a useful and more practical tool for study.

Sermorelin binds to the GHRH receptor on somatotroph cells in the anterior pituitary. This triggers the cAMP signalling pathway, leading to both synthesis and release of GH. Because it acts on the same receptor as natural GHRH, its effect remains subject to the body’s normal regulatory feedback, including inhibition by somatostatin.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (sequence Aib-His-D-2Nal-D-Phe-Lys-NH2) developed in the 1990s as part of research into growth hormone-releasing peptides (GHRPs). Rather than mimicking GHRH, it mimics ghrelin, acting as an agonist at the growth hormone secretagogue receptor, GHS-R1a.

What made Ipamorelin notable in the research literature is its selectivity. In the original animal studies, earlier GHRPs such as GHRP-6 and GHRP-2 raised ACTH and cortisol alongside GH. Ipamorelin produced GH release with no significant rise in those hormones, which is why it’s often described as the first selective GH secretagogue.

How they differ: two pathways, one target cell

The core difference is the route each peptide takes. Both end at the same pituitary cell, but they arrive through separate receptors and separate signalling cascades.

Receptor pathways of Sermorelin and Ipamorelin Sermorelin binds the GHRH receptor and Ipamorelin binds the GHS-R1a ghrelin receptor. Both receptors are on the pituitary somatotroph cell and both pathways lead to growth hormone release. Sermorelin GHRH analogue Ipamorelin Ghrelin mimetic GHRH receptor cAMP pathway GHS-R1a PLC / calcium pathway Pituitary somatotroph Growth hormone release
Different receptors, same destination: both peptides act on GH-producing cells in the anterior pituitary.

Structure and size

At 29 residues, Sermorelin is nearly five times the length of Ipamorelin. Ipamorelin’s short sequence includes non-standard and D-amino acids, which were chosen during its design to improve stability and receptor selectivity.

Mechanism

Sermorelin works through the GHRH receptor and the cAMP pathway. Ipamorelin works through GHS-R1a, which signals mainly through phospholipase C and intracellular calcium. These are distinct systems that the body uses to regulate GH, which matters for how researchers design studies.

Selectivity

Sermorelin’s activity follows the natural GHRH signal. Ipamorelin’s value in research comes from its narrow effect: GH release without the ACTH and cortisol increases seen with older GHRPs in animal models.

Why researchers study them together

Because GHRH analogues and ghrelin mimetics act through separate receptors, several studies have examined what happens when both pathways are activated at once. Research on combining GHRH with GHRP-class peptides reported a synergistic effect, meaning a GH response greater than either compound produced alone. This makes the Sermorelin and Ipamorelin pairing a common subject in studies of how the two regulatory systems interact.

Choosing between them for a study: Sermorelin suits research into the GHRH axis and physiological GH regulation. Ipamorelin suits research into ghrelin receptor signalling and selective GH secretion. Studies of pathway interaction typically involve both.

Laboratory handling and storage

Both peptides are supplied as lyophilised (freeze-dried) powder, and both follow the same general handling practice:

  • Store unopened vials at −20 °C for long-term stability, protected from light and moisture.
  • Let the vial reach room temperature before opening, to prevent condensation forming on the powder.
  • Once reconstituted for laboratory use, keep solutions refrigerated at 2–8 °C and use them promptly.
  • Avoid repeated freeze-thaw cycles, which can degrade the peptide.

Quality matters for reliable results

With a 29-residue peptide like Sermorelin, errors during synthesis such as missing or truncated sequences are more likely than with a short pentapeptide. That makes independent verification especially important. Check that each batch has HPLC purity data and mass spectrometry confirming the correct molecular weight. You can see how we test every batch on our Lab Testing page.

Sermorelin 5mg

Research-grade GHRH(1-29) analogue, HPLC tested with batch-specific COA.

View Sermorelin

Ipamorelin 5mg

Research-grade selective GH secretagogue, HPLC tested with batch-specific COA.

View Ipamorelin

Frequently asked questions

What is the main difference between Ipamorelin and Sermorelin?

They act on different receptors. Sermorelin is a GHRH analogue that binds the GHRH receptor, while Ipamorelin is a ghrelin mimetic that binds GHS-R1a. Both lead to growth hormone release from the pituitary.

Why is Ipamorelin described as selective?

In animal studies, Ipamorelin released GH without significantly raising ACTH or cortisol, unlike earlier growth hormone-releasing peptides such as GHRP-6 and GHRP-2.

Can Ipamorelin and Sermorelin be studied together?

Yes. Because they work through separate pathways, they’re often studied in combination. Research on pairing GHRH analogues with GHRP-class peptides has reported a synergistic GH response.

How should these peptides be stored?

Store lyophilised vials at −20 °C away from light and moisture. After reconstitution for laboratory use, keep solutions at 2–8 °C and avoid repeated freeze-thaw cycles.

All ApexPure products are supplied strictly for laboratory research use only. They are not intended for human or veterinary use, diagnosis or treatment. See our Research Disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *